Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes

    公开(公告)号:AU2014203008B2

    公开(公告)日:2016-03-31

    申请号:AU2014203008

    申请日:2014-06-03

    Abstract: ANTI-CEmX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES Abstract The invention pertains to the generation and utility of antibodies that can bind effectively to CEmX domain on membrane-bound IgE (mlgE) expressed on the surface of human B lymphocytes. The CEmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mlgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP peptide at the C-terminal of CEmX, have now been found to bind poorly to mlgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL and HSGQQQGLPRAAGGSVPHPR, of CEmX can bind effectively to mlgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

Patent Agency Ranking